GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (FRA:3TP0) » Definitions » Cash Ratio

Acerus Pharmaceuticals (FRA:3TP0) Cash Ratio : 0.20 (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Acerus Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Acerus Pharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2022 was 0.20.

Acerus Pharmaceuticals has a Cash Ratio of 0.20. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Acerus Pharmaceuticals's Cash Ratio or its related term are showing as below:

FRA:3TP0's Cash Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.55
* Ranked among companies with meaningful Cash Ratio only.

Acerus Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Acerus Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Cash Ratio Chart

Acerus Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 0.68 0.78 1.29 0.18

Acerus Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.18 0.17 0.06 0.20

Competitive Comparison of Acerus Pharmaceuticals's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Acerus Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acerus Pharmaceuticals's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acerus Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Acerus Pharmaceuticals's Cash Ratio falls into.



Acerus Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Acerus Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash Ratio (A: Dec. 2021 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.911/10.685
=0.18

Acerus Pharmaceuticals's Cash Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash Ratio (Q: Sep. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=3.05/15.607
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acerus Pharmaceuticals  (FRA:3TP0) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Acerus Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acerus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8
Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus Pharmaceuticals Headlines

No Headlines